V. Villemagne, C. Rowe, K. Barnham
Nov 1, 2017
Citations
0
Influential Citations
55
Citations
Quality indicators
Journal
Alzheimer's & Dementia : Translational Research & Clinical Interventions
Abstract
We are developing a second generation 8‐OH quinoline (2‐(dimethylamino) methyl‐5, 7‐dichloro‐8‐hydroxyquinoline [PBT2, Prana Biotechnology]) for targeting amyloid β (Aβ) in Alzheimer's disease (AD). In an earlier phase IIa, 3 month trial, PBT2 lowered cerebrospinal fluid Aβ by 13% and improved cognition (executive function) in a dose‐related fashion in early AD. We, therefore, sought to learn whether PBT2 could alter the Aβ‐PET signal in subjects with prodromal or mild AD, in an exploratory randomized study over a 12‐month phase in a double‐blind and a 12‐month open label extension phase trial design.